Therefore, dominant ALS/FTD causing mutations that enhance inhibitory action of CHMP2B reduce the degradative capacity of this pathway, decreasing the turn-over and causing a build-up of danger associated molecular patterns (including trigger RNAs). This evidence concerns the gene CHMP2B and frontotemporal dementia.